4DMedical Lands Mayo Clinic as Sixth Elite US Hospital to Deploy CT:VQ in 7 Months
Mayo Clinic deploys 4DMedical’s CT:VQ technology
4DMedical (ASX: 4DX) has announced that Mayo Clinic, consistently ranked the number one hospital in the United States, has initiated deployment of its CT:VQ technology for ventilation and perfusion analysis. The 4DMedical Mayo Clinic CT:VQ deployment marks a significant institutional endorsement, with Mayo becoming the sixth leading U.S. Academic Medical Center (AMC) to adopt the technology within approximately seven months of FDA clearance in September 2025.
Mayo Clinic’s decision to deploy CT:VQ sends a powerful signal to the broader U.S. healthcare market about the clinical relevance of 4DMedical’s respiratory imaging technology. As a globally respected and influential healthcare institution, Mayo’s adoption extends the company’s footprint across America’s most prestigious healthcare institutions, following successful deployments at Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, and University of Miami.
The initial 90-day agreement will support clinical workflow integration and enable Mayo’s clinical teams to build familiarity with CT:VQ’s advanced capabilities. While not financially material in isolation, the deployment positions Mayo as a potential reference site within 4DMedical’s growing network, with the opportunity to expand to full commercial terms following the initial phase.
When big ASX news breaks, our subscribers know first
What CT:VQ technology delivers for hospitals
CT:VQ is a ventilation and perfusion imaging technology that provides advanced respiratory diagnostic capabilities through standard CT imaging infrastructure. The technology offers four key clinical advantages over traditional nuclear medicine approaches:
- Eliminates the need for radioisotope and contrast administration
- Provides superior image resolution compared to nuclear medicine methods
- Integrates seamlessly into existing CT imaging workflows
- Enables access to reimbursement pathways that support sustainable clinical adoption
These technical advantages explain the rapid institutional adoption rate among elite U.S. healthcare centres. The technology’s ability to leverage existing hospital CT infrastructure removes significant implementation barriers whilst delivering enhanced diagnostic outputs for pulmonary and cardiothoracic applications.
Building an elite reference network
The 4DMedical Mayo Clinic CT:VQ deployment completes a strategic reference network of six leading Academic Medical Centers now utilising the technology. This institutional footprint, established within approximately seven months since FDA clearance, positions the company to leverage these elite sites as reference points for broader commercial deployment across the U.S. healthcare market.
| Institution | Location | Ranking Status | Deployment Status |
|---|---|---|---|
| Mayo Clinic | National Network | Number one ranked U.S. hospital | Deployed March 2026 |
| Stanford | California | Leading U.S. Academic Medical Center | Deployed |
| Cleveland Clinic | Ohio | Leading U.S. Academic Medical Center | Deployed |
| UC San Diego Health | California | Leading U.S. Academic Medical Center | Deployed |
| University of Chicago Medicine | Illinois | Leading U.S. Academic Medical Center | Deployed |
| University of Miami | Florida | Leading U.S. Academic Medical Center | Deployed |
The reference site strategy positions 4DMedical (ASX: 4DX) to convert institutional credibility into broader commercial contracts. Combined with the Philips distribution partnership announced previously, the company has established both the clinical validation and commercial infrastructure to support market penetration across the broader U.S. healthcare system.
Initial deployment structure
Mayo Clinic’s engagement follows 4DMedical’s established deployment approach, utilising a 90-day initial agreement that focuses on clinical workflow integration rather than immediate commercial terms. This structure enables Mayo’s clinical teams to build familiarity with CT:VQ’s advanced diagnostic outputs and assess its application across a range of pulmonary and cardiothoracic use cases.
Whilst the initial agreement is not financially material, it creates a pathway to full commercial terms following the integration phase. Mayo’s influence on clinical practice, treatment guidelines, and technology adoption across U.S. and global health systems positions the institution as a particularly valuable reference site within 4DMedical’s growing network.
CEO perspective on the milestone
Managing Director and CEO Andreas Fouras emphasised the strategic significance of Mayo Clinic’s decision to deploy CT:VQ, highlighting both the institution’s unparalleled reputation and the broader signal it sends to the U.S. healthcare market.
Andreas Fouras, MD/CEO and Founder
“When the world’s number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ.”
Fouras noted that the pace of institutional adoption is unprecedented, with six of America’s leading AMCs established within approximately seven months since FDA clearance. He stated that no other technology in the respiratory imaging space has achieved this level of clinical adoption in such a short timeframe.
The CEO indicated that 4DMedical’s sales pipeline has never looked stronger, with the combined platform of elite AMC reference sites and the Philips partnership building what he described as an unassailable platform for CT:VQ adoption.
The next major ASX story will hit our subscribers first
Commercial momentum and what comes next
The 4DMedical Mayo Clinic CT:VQ deployment caps a period of extraordinary commercial momentum for the company, with six leading Academic Medical Centers now utilising the technology within approximately seven months of FDA clearance in September 2025. The pace of elite institutional adoption validates both the clinical value proposition of CT:VQ and the company’s strategic approach of establishing reference sites at prestigious healthcare institutions.
Mayo Clinic’s influence on clinical practice and treatment guidelines across U.S. and global health systems creates a potential catalyst for broader commercial deployment as the institution’s clinicians integrate CT:VQ into their workflows. Combined with 4DMedical (ASX: 4DX)‘s growing commercial pipeline and Philips distribution partnership, the deployment strengthens the company’s position heading into the broader commercialisation phase.
Management has indicated that further progress will be shared soon, with the sales pipeline reported to be at its strongest level to date.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements delivered straight to your inbox the moment they break.